Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adhesion molecule with Ig-like domain 1 (AMIGO1)
- Target
- AMIGO1
- Molecular classification
- Cell adhesion molecule, Immunoglobulin-like domain protein, Potassium channel regulator
01
Overview
Adhesion molecule with Ig-like domain 1 (AMIGO1) is a cell-surface protein belonging to the immunoglobulin superfamily. It promotes neurite growth, fasciculation, and contributes to myelination and regeneration in the nervous system. AMIGO1 mediates both homophilic and heterophilic cell-cell adhesion, influences signal transduction through its intracellular domain, and acts as a regulator of voltage-dependent potassium channel gating (notably in KCNB1 complexes). It is specifically and highly expressed in neural tissues, especially the brain, and plays critical roles in both development and adult nervous system plasticity
- Other names
- Amphoterin-induced protein 1AMIGOAMIGO-1Alivin-2ALI2KIAA1163Amphoterin-induced gene and open reading frameAmphoterin-induced gene and ORF
02
Mechanism of action
For interacting compounds (if any): Modulation of potassium channel gating via interaction with AMIGO1-KCNB1 complexes; indirect regulation of neuronal signaling
03
Biological functions
Cell-cell adhesion (homophilic and heterophilic)Promotion of neurite growth and fasciculationMyelination of neural axonsNervous system developmentChannel regulation (modulates voltage-dependent potassium channels)Neural plasticity and regeneration
04
Disease associations
Neurodegenerative disease (implicated in neural development and plasticity)Possible role in cancer (expressed in some tumors per tissue profiling)Other (reported associations with rare conditions like Tungiasis and Median Arcuate Ligament Syndrome; limited direct evidence)
05
Safety considerations
As research is early-stage, notable safety concerns or therapeutic challenges specific to AMIGO1 targeting are not establishedtheoretical risks may relate to disruption of neural development or plasticity
06
Biomarkers
There are no validated clinical biomarkers for patient selection or efficacy monitoring for AMIGO1 as of nowtissue-specific expression patterns (especially in neural tissue) may serve as research biomarkers
Beyond the preview
Go deeper on Adhesion molecule with Ig-like domain 1 (AMIGO1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adhesion molecule with Ig-like domain 1 (AMIGO1).